• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   [email protected]
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • Scopus İndeksli Yayınlar Koleksiyonu
  • View Item
  •   [email protected]
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • Scopus İndeksli Yayınlar Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Does nimodipine, a selective calcium channel blocker, impair chondrocyte proliferation or damage extracellular matrix structures?

Thumbnail

View/Open

Tam Metin / Full Text (4.302Mb)

Access

info:eu-repo/semantics/openAccess

Date

2019

Author

Kaplan, Necati
Yılmaz, İbrahim
Karaarslan, Numan
Kaya, Yasin Emre
Yaşar, Şirin, Duygu
Özbek, Hanefi

Metadata

Show full item record

Citation

Kaplan, N., Yılmaz, İ., Karaarslan, N., Kaya, Y. E., Şirin, D. Y. ve Özbek, H. (2019). Does nimodipine, a selective calcium channel blocker, impair chondrocyte proliferation or damage extracellular matrix structures? Current Pharmaceutical Biotechnology. 20(6), 517-524. https://doi.org/10.2174/1389201020666190506124548

Abstract

Background: The study aimed to investigate the effects of the active ingredient, nimodipine, on chondrocyte proliferation and extracellular matrix (ECM) structures in cartilage tissue cells. Methods: Chondrocyte cultures were prepared from tissues resected via surgical operations. Nimodipine was then applied to these cultures and molecular analysis was performed. The data obtained were statistically calculated. Results: Both, the results of the (3-(4,5 dimethylthiazol2-yl)-2,5-diphenyltetrazolium (MTT) assay and the fluorescence microscope analysis [a membrane permeability test carried out with acridine orange/propidium iodide staining (AO/PI)] confirmed that the active ingredient, nimodipine, negatively affects the cell cultures. Conclusion: Nimodipine was reported to suppress cellular proliferation; chondroadherin (CHAD) and hypoxia-inducible factor-1 alpha (HIF-1α) expression thus decreased by 2.4 and 1.7 times, respectively, at 24 hrs when compared to the control group (p < 0.05). Furthermore, type II collagen (COL2A1) expression was not detected (p < 0.05). The risk that a drug prescribed by a clinician in an innocuous manner to treat a patient by relieving the symptoms of a disease may affect the proliferation, differentiation, and viability of other cells and/or tissues at the molecular level, beyond its known side effects or adverse events, should not be forgotten.

WoS Q Kategorisi

Q3

xmlui.dri2xhtml.METS-1.0.item-scopusquality

Q2

Source

Current Pharmaceutical Biotechnology

Volume

20

Issue

6

URI

https://doi.org/10.2174/1389201020666190506124548
https://hdl.handle.net/20.500.12511/4702

Collections

  • Makale Koleksiyonu [3261]
  • PubMed İndeksli Yayınlar Koleksiyonu [3567]
  • Scopus İndeksli Yayınlar Koleksiyonu [5480]
  • WoS İndeksli Yayınlar Koleksiyonu [5660]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Guide | Contact |

[email protected]

by OpenAIRE
Advanced Search

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsInstitution AuthorORCIDTitlesSubjectsTypeLanguageDepartmentCategoryWoS Q ValueScopus Q ValuePublisherAccess TypeThis CollectionBy Issue DateAuthorsInstitution AuthorORCIDTitlesSubjectsTypeLanguageDepartmentCategoryWoS Q ValueScopus Q ValuePublisherAccess Type

My Account

LoginRegister

Statistics

View Google Analytics Statistics

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Guide || Library || İstanbul Medipol University || OAI-PMH ||

Kütüphane ve Dokümantasyon Daire Başkanlığı, İstabul, Turkey
If you find any errors in content, please contact: [email protected]

Creative Commons License
[email protected] by İstanbul Medipol University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

[email protected]:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.